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The detection of hundreds of thousands of new cases of leprosy every year suggests that transmission of
Mycobacterium leprae infection still continues. Unfortunately, tools for identification of asymptomatic disease
and/or early-stage M. leprae infection (likely sources of transmission) are lacking. The recent identification of
M. leprae-unique genes has allowed the analysis of human T-cell responses to novelM. leprae antigens. Antigens
with the most-promising diagnostic potential were tested for their ability to induce cytokine secretion by using
peripheral blood mononuclear cells from leprosy patients and controls in five different areas where leprosy is
endemic; 246 individuals from Brazil, Nepal, Bangladesh, Pakistan, and Ethiopia were analyzed for gamma
interferon responses to five recombinant proteins (ML1989, ML1990, ML2283, ML2346, and ML2567) and 22
synthetic peptides. Of these, the M. leprae-unique protein ML1989 was the most frequently recognized and
ML2283 the most specific for M. leprae infection/exposure, as only a limited number of tuberculosis patients
responded to this antigen. However, all proteins were recognized by a significant number of controls in areas
of endemicity. T-cell responses correlated with in vitro response to M. leprae, suggesting that healthy controls
in areas where leprosy is endemic are exposed toM. leprae. Importantly, 50% of the healthy household contacts
and 59% of the controls in areas of endemicity had no detectable immunoglobulin M antibodies to M.
leprae-specific PGL-I but responded in T-cell assays to >1 M. leprae protein. T-cell responses specific for
leprosy patients and healthy household contacts were observed for ML2283- and ML0126-derived peptides,
indicating that M. leprae peptides hold potential as diagnostic tools. Future work should concentrate on the
development of a sensitive and field-friendly assay and identification of additional peptides and proteins that
can induce M. leprae-specific T-cell responses.
Leprosy is a curable infectious disease caused by Mycobac-
terium leprae involving cutaneous tissue and peripheral nerves
and causing skin lesions, nerve degeneration, anesthesia, and
deformities. Important advances in antimycobacterial therapy
in the 1980s were the basis of the effort by the World Health
Organization to eliminate leprosy as a public health problem
(i.e., to achieve a global prevalence of 1/10,000) by the year
2000. The leprosy elimination program has had a massive effect
on the registered number of cases, which fell to 212,802 world-
wide at the beginning of 2008 (1). In addition, a reported
year-end prevalence below 1 per 10,000 in 2007 was obtained
in all but three countries with populations of 1 million (Bra-
zil, Nepal, and East Timor). The global number of new cases
detected has continued to decrease dramatically in the last 5
years at an average rate of nearly 20% per year (1). Notwith-
standing these numbers, hundreds of thousands of new cases of
leprosy are still detected every year (254,525 worldwide in
2007), and pockets of high endemicity, where leprosy remains
a public health problem, still occur in Angola, Brazil, the Cen-
tral African Republic, India, Madagascar, Nepal, and the
United Republic of Tanzania. This demonstrates that active
transmission is occurring in the face of an antibiotic-based
leprosy elimination strategy, and this transmission is thought to
be caused by the continuing reservoir of M. leprae-infected
contacts and persons with subclinical leprosy. Furthermore, a
population survey in Bangladesh showed that even in the pres-
ence of a strong leprosy control program, the actual number of
leprosy cases was about five times higher than the registered
number of cases (17). Therefore, timely detection and prompt
multidrug treatment are of utmost importance. However, di-
agnosis of leprosy is classically based on clinical manifestations
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as well as labor-intensive and time-consuming laboratory or
histological evaluation. The scarcity of symptoms in early dis-
ease and the lack of bacteria in paucibacillary (PB) patients
contribute to the difficulty of diagnosis. Tools for diagnosis of
asymptomatic M. leprae infection are not available yet, nor is it
possible to predict disease development in exposed individuals.
While the existence of high-titer immunoglobulin M (IgM)
antibodies to phenolic glycolipid-I (PGL-I) has allowed the
development of user-friendly kit-based tests, these are appli-
cable largely to multibacillary (MB) leprosy patients (9) and
have little relevance to those with PB or asymptomatic leprosy
who show vigorous cellular rather than humoral immune re-
sponses (18). Thus, in order to allow informed decision making
on who needs treatment at a preclinical stage, new tests that
detect M. leprae infection and/or measure biomarkers that pre-
dict disease development in infected individuals are required.
Cellular tests have in the past relied on the use of complex
and usually incompletely defined mixtures of M. leprae com-
ponents (4) and have limited value due to their inherent high
cross-reactivity with other mycobacteria, which is particularly
problematic in countries with high incidence rates of tubercu-
losis (TB), routine Mycobacterium bovis BCG vaccination, and
high levels of exposure to environmental mycobacteria. In our
attempts to develop simple assays based on cell-mediated im-
mune (CMI) responses particularly for identification of asymp-
tomatic leprosy, we were encouraged by the recent develop-
ment of two commercially available gamma interferon (IFN-)
release assays for specific diagnosis of M. tuberculosis infection
(11, 19) that exploit antigens (ESAT-6, CFP-10, and TB7.7)
that are selectively expressed by M. tuberculosis and deleted in
nonvirulent BCG strains and most other nontuberculous my-
cobacteria. However, the M. leprae homologues of ESAT-6 and
CFP-10 (ML0049 and ML0050, respectively) were recognized
well by T cells from M. tuberculosis-infected individuals, de-
spite limited amino acid sequence homology (36% and 40%,
respectively), thereby limiting the diagnostic potential of
ESAT-6 and CFP-10 in areas of leprosy endemicity with high
prevalences of TB (15, 16).
Through comparative analysis of annotated mycobacterial
genomes, several investigators selected putative open reading
frames that were found only in the M. leprae genome and
lacked homologues in any of the (myco)bacterial databases
available at that time. Further bioinformatic analyses of these
M. leprae-unique sequences identified several (hypothetical)
antigens that were tested for their ability to induce in vitro
T-cell responses in M. leprae-infected individuals (2, 3, 13, 14,
20). Two initial studies that provided a basis for the currently
described study were performed with a Brazilian population
(Rio de Janeiro, Brazil), using M. leprae-unique proteins and
peptides arising from the above-described approach (13, 20).
Together, these studies identified several proteins and peptides
with the potential to identify M. leprae-infected subjects.
T-cell responses are HLA restricted, which may pose a prob-
lem for the global applicability of diagnostic T-cell-based as-
says in genetically diverse populations. A previous study using
M. leprae-derived peptides showed considerable variation in
peptide reactivity at different sites (8). Thus, in order to esti-
mate the potential of the peptides for detecting M. leprae-
specific T-cell immunity in the context of genetically different
backgrounds, we selected the most promising peptides (n 
22) and proteins (n  5) from the previous studies in Brazil,
four other countries of leprosy endemicity in Asia (Nepal,
Bangladesh, and Pakistan) and Africa (Ethiopia), and an ad-
ditional site in west central Brazil (Goia´s State).
Once identified, M. leprae antigens that provide specific im-
mune responses in leprosy patients and exposed individuals at
all five sites of endemicity could be used to develop a rapid
diagnostic test for early detection of leprosy. Such a test could
be used in field studies to estimate how many individuals living
in areas of endemicity have been infected with M. leprae and to
identify those in high-risk groups who require treatment or
prophylaxis.
MATERIALS AND METHODS
General procedure of the study. Five laboratories, situated in areas where
leprosy is endemic, were involved in this study: Tropical Pathology and Public
Health Institute, Federal University of Goia´s, Goiaˆnia, Brazil; Mycobacterial
Research Laboratory, Anandaban Hospital, Anandaban, Nepal; International
Center for Diarrheal Disease Research Bangladesh, Dhaka, Bangladesh; Aga
Khan University, Karachi, Pakistan; and Armauer Hansen Research Institute,
Addis Ababa, Ethiopia. To ensure reproducibility of data throughout the study
at each site, all experiments carried out by different laboratories involved were
performed according to standard operating procedures and each site was pro-
vided with identical reagents.
Production and testing ofM. leprae recombinant proteins.M. leprae candidate
genes were amplified by PCR from genomic DNA of M. leprae and cloned using
the Gateway technology platform (Invitrogen, Carlsbad, CA) with a pDEST17
expression vector containing an N-terminal histidine tag (Invitrogen, Carlsbad,
CA) (12). Sequencing was performed on selected clones to confirm the identities
of all cloned DNA fragments. Recombinant proteins were overexpressed in
Escherichia coli BL21(DE3) and purified as previously described to remove
possibly present endotoxin (12). Each purified M. leprae protein was analyzed by
12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, followed by
Coomassie brilliant blue staining and Western blotting with an anti-His antibody
(Invitrogen, Carlsbad, CA) to confirm size and purity. Endotoxin contents were
below 50 IU/mg recombinant protein, as tested using a Limulus amebocyte lysate
assay (Cambrex, East Rutherford, NJ). All recombinant proteins were tested to
exclude antigen-nonspecific T-cell stimulation and cellular toxicity potentially
induced by 6-day incubation with protein (as estimated by increased or decreased
responses to medium or phytohemagglutinin [PHA], respectively), using IFN-
release assays with peripheral blood mononuclear cells (PBMC) of BCG-nega-
tive, Mantoux skin test-negative, healthy Dutch donors recruited at Leiden Uni-
versity Medical Center (LUMC), The Netherlands. None of these controls had
experienced any known prior contact with leprosy or TB patients (see Fig. S1 in
the supplemental material).
M. leprae whole-cell sonicate. Irradiated, armadillo-derived M. leprae whole
cells were probe sonicated with a Sanyo sonicator to 95% breakage (Colorado
State University, Fort Collins, CO, through NIH/NIAID Leprosy Contract N01-
AI-25469).
Synthetic peptides. Sequences of M. leprae peptides were selected on the basis
of data obtained in previous studies (2, 14, 20). Peptides were synthesized
commercially (Mimotopes, San Diego, CA) with free amino and carboxy termini
at a 1-mmol scale. Each peptide was dissolved in endotoxin-free distilled water,
sonicated, aliquoted, and relyophilized to dryness.
Study subjects. Ethical approval of the study protocol was obtained through
the appropriate local ethics committees. Written, informed consent was obtained
from all individuals before venipuncture. At each site, 50 human immunodefi-
ciency virus-negative individuals were recruited: 10 BL/LL leprosy patients, 10
BT/TT leprosy patients, 10 healthy household contacts (HHCs) of BL/LL pa-
tients, 10 healthy individuals from the same area of endemicity (the EC group),
and 10 smear-positive pulmonary TB patients. In Ethiopia, only six HHCs were
recruited. Leprosy patients were recruited between September 2006 and March
2007 and treated with chemotherapy for less than 3 months, with no signs of
leprosy reactions. Leprosy was diagnosed on the basis of clinical, bacteriological,
and histological observations and classified on the basis of a skin biopsy, which
was evaluated by qualified personnel using the methods of Ridley and Jopling
(19a). Leprosy patient recruitment was performed at the following institutes:
Centro de Refereˆncia em Diagno´stico e Terapeˆutica/Reference Center for Di-
agnosis and Treatment, Goiaˆnia, Brazil; Anandaban Hospital, Anandaban, Ne-
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pal; Leprosy Control Institute & Hospital, Dhaka, Bangladesh; Marie Adelaide
Leprosy Center Saddar, Karachi, Pakistan; and ALERT Hospital, Addis Ababa,
Ethiopia.
HHCs were defined as adults who had been living in the same house as a
BL/LL index patient for at least the preceding 6 months. EC individuals were
assessed for the absence of signs and symptoms of TB and leprosy. Staff members
working in the leprosy centers or clinics were excluded as EC individuals. The TB
patients were required to have been on chemotherapy for at least 3 months to
enable some recovery of T-cell function. For all subjects, the presence or absence
of a BCG scar was recorded.
Lymphocyte stimulation tests. Venous blood samples were obtained from
study participants in heparinized tubes and PBMC isolated by Ficoll density
centrifugation. PBMC (2  106 cells/ml) were plated in triplicate cultures in
96-well round-bottom plates (Costar Corporation, Cambridge, MA) in 200 l/
well of adoptive immunotherapy medium (AIM-V; Invitrogen, Carlsbad, CA)
supplemented with 100 U/ml penicillin, 100 g/ml streptomycin, and 2 mM
L-glutamine (Invitrogen, Carlsbad, CA). Synthetic peptides, recombinant pro-
tein, M. leprae whole-cell sonicate, or purified protein derivative of M. tubercu-
losis (Mycos, Loveland, CO) was added to give a final concentration of 10 g/ml.
As a positive-control stimulus, a concentration of 1 g/ml PHA (Sigma, St. Louis,
MO) was used. After 6 days of culture at 37°C at 5% CO2 and 90% relative
humidity, 75-l supernatants were removed from each well, and triplicates were
pooled and frozen in aliquots at 20°C until further analysis.
IFN- ELISA. IFN- levels were determined by an enzyme-linked immunosor-
bent assay (ELISA; U-CyTech, Utrecht, The Netherlands) (14). The cutoff value
for defining positive responses was set beforehand at 100 pg/ml. The assay
sensitivity level was 40 pg/ml. Values for unstimulated cell cultures were typically
20 pg/ml. Lyophilized supernatant of PHA cultures of PBMC from an anon-
ymous buffycoat (LUMC, The Netherlands) was provided to all five sites as a
reference positive-control supernatant.
PGL-I ELISA. IgM antibodies against M. leprae PGL-I were detected with
natural disaccharide of PGL-I linked to bovine serum albumin (0.01 ng/well;
provided through NIH/NIAID Leprosy Contract N01-AI-25469) as previously
described (5). Serum dilutions (100 l/well; 1:300) were incubated at 37°C for 90
min in flat-bottomed microtiter plates (Nunc) coated with natural disaccharide of
PGL-I linked to bovine serum albumin. After a wash, diluted enzyme-linked
secondary antibody solution (100 l/well) was added to all wells and incubated at
37°C for 30 min. After another wash, diluted TMB (3,3	,5,5	-tetramethylbenzi-
dine) solution (100 l/well) was added to all wells and incubated in the dark for
15 min at room temperature. The reaction was stopped by adding 100 l/well 0.5
N H2SO4. Absorbance was determined at a wavelength of 450 nm. Samples with
net optical densities at 450 nm above 0.56 were considered positive. ELISA
performance was monitored using a positive and a negative control serum sample
on each plate.
Statistical analysis. Differences in IFN- levels between test groups were
analyzed with the two-tailed Mann-Whitney U test for nonparametric distribu-
tion, using GraphPad Prism (version 4). P values were corrected for multiple
comparisons. The statistical significance level used was P values of 0.05.
RESULTS
T-cell recognition of M. leprae antigens in areas where lep-
rosy is endemic. In order to develop tools that can be used to
detect M. leprae-specific T-cell immunity in the context of ge-
netically different backgrounds, a study population of 246 in-
dividuals was recruited at five institutes in areas where leprosy
is endemic (Goiaˆnia, Brazil; Anandaban, Nepal; Dhaka, Ban-
gladesh; Karachi, Pakistan; and Addis Ababa, Ethiopia). At
each site, 10 individuals from five test groups (MB, PB, HHC,
EC, and TB) were targeted (Table 1). Throughout this study
IFN- was used as a readout for T-cell responses directed
against M. leprae antigens, as it is a stable and robust Th1
cytokine. Before IFN- analysis of test samples, the perfor-
mances of the selected IFN- assay were compared for the five
sites of endemicity by using identical batches of human IFN-
standard. This showed that all five laboratories obtained over-
lapping IFN- standard curves with similar ranges of sensitivity
(data not shown).
In order to identify antigens that induce M. leprae-specific
T-cell responses in vivo, all individuals were analyzed for cen-
tral memory T-cell responses against 5 recombinant proteins
that had been identified as M. leprae unique (ML1989,
ML1990, ML2283, and ML2567 [13] and ML2346 [10]) and 22
M. leprae peptides (Table 2) (2, 20) in a 6-day assay using
isolated PBMC. In general, IFN- production in response to
the control stimuli PHA, M. leprae (Table 3), and purified
protein derivative (data not shown) was as predicted according
to the subject group at all five sites. IFN- responses in un-
stimulated control samples were absent or low. Individuals
with high values for in vitro unstimulated medium (100 pg/
ml) were excluded from the study and replaced, as were indi-
viduals lacking responses against PHA. IFN- data obtained at
each of the five test sites of leprosy endemicity showed that all
five recombinant M. leprae proteins induced IFN- responses,
although with various degrees of specificity and interindividual
differences (Fig. 1). Overall, the frequencies of responders to
the proteins were highest in Nepal and lowest in Brazil (see
Fig. S2 in the supplemental material).
Since the amounts of IFN- obtained at all five sites for
PHA and M. leprae whole-cell sonicates were mostly within
similar ranges (Table 3), IFN- production in response to each
recombinant M. leprae protein was analyzed by combining in-
dividuals of all sites per test group (Fig. 1). These cumulative
TABLE 1. Participating study sites and study populations
Site Prevalencea Category BI(mean)
Sex
ratiob
Mean
age
(yr)
Goia´s State (Brazil) 4.19 MB 2.07 6/4 47
PB 0 4/6 40
HHC c 4/6 43
EC  4/6 27
TB  5/5 43
Anandaban (Nepal) 1.56 MB 2.7 9/1 42
PB 0.08 7/3 35
HHC  5/5 33
EC  6/4 20
TB  6/4 25
Dhaka (Bangladesh) 2.45 MB 1.60 7/3 34
PB 0.30d 7/3 38
HHC  7/3 38
EC  7/3 31
TB  7/3 29
Karachi (Pakistan) 0.39 MB 2.4 7/3 41
PB 0 4/6 32
HHC  4/6 39
EC  6/4 30
TB  4/6 28
Addis Ababa (Ethiopia) 0.60 MB 2.35 7/3 35
PB 0.15e 8/2
HHC  6/0 37
EC  6/4 20
TB  4/6 24
a Prevalence per 10,000 individuals.
b Male/female ratio.
c , not applicable.
d The positive bacterial index (BI) was caused by one individual with a BI of 3.
e The positive bacterial index (BI) was caused by one individual with a BI
of 1.5.
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data showed that in all test groups, ML1989 was recognized
(i.e., producing 100 pg/ml IFN-) most frequently, ranging
from 30% responders in the BL/LL group and 46% in the
HHC group to 56% in the BT/TT group and even 70% in the
EC group. Responses to ML2283 were observed least fre-
quently, as only three TB patients and nine BL/LL patients
recognized this protein.
Although BT/TT patients, HHCs, and, to a lesser extent,
BL/LL patients responded well to most of the five recombinant
M. leprae proteins, responses were not specific for these
groups, as the majority of the EC group showing in vitro T-cell
responses to M. leprae whole-cell sonicate responded equally
well to these proteins (Fig. 1).
T-cell responses to the proteins corresponded with in vitro
responses to M. leprae whole-cell sonicate, except for two M.
leprae-negative EC individuals whose PBMC were activated by
ML1989 (Fig. 1).
In contrast to IFN- responses induced by recombinant M.
leprae proteins, induction of T-cell responses to the 22 M.
leprae peptides (Table 2) was limited (Fig. 2); although each
peptide was recognized at least once, the number of individuals
responding significantly (100 pg/ml) to one peptide or more
was lower than that for protein recognition (for BL/LL pa-
tients, 16%; for BT/TT patients, 20%; for HHCs, 20%; for EC
individuals, 20%; and for TB patients, 22%). This confirms
what we observed previously (20), namely, that peptides induce
lower IFN- responses and that a lower number of individuals
respond to peptides. No peptide responses were detected in
any individuals from Brazil. ML1420 p70, ML0394 p48, and
ML0308 p56 were recognized most frequently by PBMC of M.
leprae-exposed individuals but were also recognized by those of
TB patients (n  6, n  6, and n  7, respectively) and EC
individuals (n  3, n  2, and n  3, respectively). Overall,
peptide recognition per se was not limited to M. leprae-infected
patients or HHCs, as the percentages of individuals responding
to 1 M. leprae peptide were similar among both EC individ-
uals and TB patients. However, individuals responding to the
peptides also responded to M. leprae whole-cell sonicate.
Three M. leprae-unique peptides, ML2283 p19 (14), ML2283
p20 (14), and ML0126 p81 (20), were specific in all five pop-
ulations, as they were recognized only by T cells from subjects
in the BL/LL, BT/TT, and HHC groups, not by any EC
individuals or TB patients.
Added value of T-cell responses to M. leprae-specific anti-
PGL-I IgM antibodies. All individuals were tested for M. lep-
rae-specific IgM antibodies to PGL-I. Anti-PGL-I IgM anti-
bodies were present in 46/50 BL/LL patients, in 19/50 BT/TT
patients, in 6/46 HHCs, in 3/50 EC individuals, and in 13/50 TB
patients (Table 4) (optical densities at 450 nm of 0.56; range,
0.200 to 2.819).
In order to analyze whether CMI responses directed against
M. leprae antigens may provide any added value in detecting M.
leprae exposure/infection in comparison to currently available
assays that measure M. leprae-specific humoral immunity, T-
cell reactivities to the five M. leprae proteins versus humoral
immune responses against M. leprae were analyzed (Table 4
and Fig. 3). In the HHC group, 39/46 individuals did not have
detectable levels of anti-PGL-I IgM antibodies. Interestingly,
23/39 (59%) of these exposed individuals responded to one or
more of the five proteins unique to M. leprae (Fig. 3). In the EC
group, 47/50 individuals were seronegative for antibodies to M.
leprae-specific PGL-I, and 68% (32/47) of these individuals
showed T-cell responses to one or more M. leprae antigens.
DISCUSSION
Leprosy and its associated disabilities will be with us well
into the future, as recognized in the World Health Organiza-
tion’s global strategy for 2006 to 2010 (1). Clearly, the methods
TABLE 2. Amino acid sequences of synthetic M. leprae peptides
Peptide Amino acid sequence Gene annotation
p43 STNYVNLSTIGIKLKI ML1989
p40 VGFVNAWSLLFYPPQGWESP ML1990
p19 PLARELYRKIDCYSEEDLVE ML2283
p20 DCYSEEDLVEIAAKSLRATI ML2283
p92 LQAYSNLFGRTSAMQ ML2452c
p70 MQEYRGLTSHTPCCR ML1420
p51 AAALEQLLGQTADVA ML1057
p73 DAEWLKLTSLGLRPR ML1829
p63 GINLPKDELTAFGRK ML0757c
p86 VYLYNYLLAETSHVL ML0840c
p88 DDIWRTLASAVITGN ML1189c
p48 QLMYLIEITSETKAL ML0394c
p81 GDVWKSIVHLRSTRH ML0126
p40 RVSYGSECRSGNCLR ML0008c
p54 NHAVSSDFKTRSTNT ML2567
p74 VKAVVDDVNAILLTGR ML1915
p69 RLDGTTLEV ML1419c
p56 FDEYRAMFALSAMDL ML0308
p85 NYEVSPIFARWPRNR ML0638
p49 GRYYAEINSAKMYFG ML1057
p1 SRGFDEYRAMFALSAMDLNATI ML0308
p2 SLLMQEYRGLTSHTP ML1420
TABLE 3. Mean IFN- production levels in response to control stimuli
Group
Mean (pg/ml) for indicated stimulusa
M. leprae PHA
A B C D E A B C D E
BL/LL 781 314 435 59 748 5,553 3,387 2,407 637 5,221
BT/TT 3,014 1,882 750 953 1,799 4,940 5,331 3,087 1,826 4,814
HHC 2,848 903 1,897 1,199 2,240 5,081 4,608 4,658 745 3,181
EC 1,305 2,186 1,524 2,165 2,774 4,900 4,946 2,883 879 7,325
TB 68 1,778 248 444 1,781 5,523 4,996 1,732 705 5,032
a Values shown were calculated from single values corrected for background responses. Sites: A, Brazil; B, Nepal; C, Bangladesh; D, Karachi; and E, Ethiopia.
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and knowledge available to date have not been sufficient to
eliminate leprosy. Transmission continues because tools for
early, preclinical diagnosis of M. leprae infection, which is likely
to be a major source of unidentified transmission, are lacking.
Thus, the design of better tools for detection of preclinical M.
leprae infection, which would allow introduction of multidrug
therapy at an early stage, has been an important goal in leprosy
research since the beginning of the 21st century.
The successful use of the M. tuberculosis-specific peptides
ESAT-6 (Rv3875), CFP-10 (Rv3874), and TB7.7 (Rv2654) for
TB diagnostics among humans (11) supported our belief in the
possibilities for using peptides in CMI response-based diag-
FIG. 1. IFN- production by PBMC induced in response to five recombinant M. leprae proteins (ML1989, ML1990, ML2283, ML2346, and
ML2567) derived from six test groups: healthy EC individuals with (E; EC Mlep; n  43) or without (; EC Mlep; n  7) in vitro T-cell
responses to M. leprae whole-cell sonicate, (borderline) lepromatous leprosy patients (F; BL/LL; n 50), (borderline) tuberculoid leprosy patients
(; BT/TT; n  50), HHCs (Œ; n  46), and TB patients (; n  50). For each test group, data from five sites where leprosy is endemic (Brazil,
Nepal, Bangladesh, Pakistan, and Ethiopia) are combined. All values are corrected for medium values. Median values per test group are indicated
by short horizontal lines. For each test group, the number of IFN- responders (100 pg/ml, as indicated by the horizontal line) versus the total
number of individuals in the group and the percentage is indicated below the x axis.
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FIG. 2. IFN- production corrected for medium values induced in response to 22 synthetic M. leprae peptides (Table 2) by 6-day incubation of PBMC
derived from MB leprosy patients (n 50), PB leprosy patients (n 50), HHCs (n 46), healthy controls in areas of endemicity (EC group), or TB patients
(n 50). Black squares indicate IFN- production of 100 pg/ml; gray squares indicate IFN- production between 50 and 100 pg/ml; white squares indicate
IFN- production50 pg/ml. Numbers in each test group indicate the total number of individuals per group responding with100 pg/ml to a certain peptide.
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nostic tests for leprosy. The availability of the genome se-
quence of M. leprae (6), together with new techniques in bioin-
formatics, has thus enabled us to identify M. leprae-unique
candidate proteins (2, 13, 20), as well as peptides (20) or
combinations of peptides (14), that can be applied to detect M.
leprae-specific T-cell responses.
In earlier studies situated in Brazil (14, 20), M. leprae pro-
teins induced higher levels of IFN-, but T-cell responses to
peptides were found to be more specific. Therefore, both M.
leprae proteins and peptides that had shown promising speci-
ficity in these studies were analyzed in the current multicenter
study, which used samples from Brazil, Nepal, Bangladesh,
Pakistan, and Ethiopia.
The results of our study show that all proteins were indeed
recognized strongly by PBMC of BT/TT patients and HHCs,
with ML2283 being the most specific protein, as it was not
frequently recognized in TB patients (Fig. 1). However, the
majority of the EC group responded as well to the M. leprae
proteins and peptides (Fig. 1 and 2) as did the individuals
known to have been exposed to or infected by M. leprae, de-
spite the fact that all the antigens had been selected on the
basis of their unique sequences in M. leprae. In addition, T-cell
responses against M. leprae antigens were observed in TB pa-
tients. Since M. leprae-positive EC individuals and TB patients
were also responding to M. leprae whole-cell sonicate and none
of the antigens induced any IFN- in healthy controls derived
from countries of nonendemicity (see Fig. S1 in the supple-
mental material), the possibility remains that the response
against M. leprae-unique antigens is caused by previous expo-
sure of EC individuals and TB patients to M. leprae. This would
then indicate that exposure to/infection by M. leprae may be
occurring in this population at much higher rates than previ-
ously thought (17). Importantly, three M. leprae-unique pep-
tides, ML2283 p19 (14), ML2283 p20 (14), and ML0126 p81
(20), were specific in all five areas of endemicity, as these
peptides were recognized only in BL/LL patients, BT/TT pa-
tients, and HHCs but to a much lesser extent (50 to 100 pg/ml)
in EC individuals or not at all in TB patients. Since HLA
restriction allows a relatively low number of individuals to
respond to these peptides, additional M. leprae peptides will
have to be analyzed in order for a combination of peptides that
detects T-cell responses to M. leprae in a specific fashion to be
obtained. Furthermore, the variability of T-cell responses in
cultures stimulated with peptides at the five different test sites
(Fig. 2) highlighted the necessity of testing M. leprae peptides
in different populations in order to design diagnostic tools that
are applicable in various areas of endemicity.
Since a combination of PGL-I serology with assays based on
CMI responses against M. leprae antigens may allow detection
of most forms of leprosy (PB and MB), including preclinical
leprosy, we analyzed whether these five M. leprae proteins
represented potential added value in diagnosing early infec-
tion: T-cell responses against these proteins were detected in
59% of M. leprae-exposed HHCs that did not have antibodies
to PGL-I (Fig. 3), indicating a serologically undetected but
potentially M. leprae-infected group.
The development of a sensitive, specific, and field- and user-
friendly test (7) which is also affordable can have a significant
impact on leprosy control programs in countries of endemicity.
In search of new diagnostic tools for leprosy, we have thus far
found that T-cell responses to M. leprae proteins and peptides
can be detected in a 6-day PBMC assay. In future studies, we
will aim to maintain the M. leprae specificity of the peptides as
observed here in the PBMC stimulation assay for ML2283 p19,
ML2283 p20, and ML0126 p81 and, in addition, screen more
M. leprae proteins and peptides to identify sequences that to-
gether induce CMI responses in the context of multiple HLA
alleles, thereby providing coverage for diagnostics in different
regions of endemicity. Since T-cell responses to M. leprae an-
tigens are more sensitive in assays using PBMC than in whole-
blood assays (data not shown), we will also assess whether the
conditions of M. leprae peptide-based whole-blood assays can
be optimized.
Finally, it is crucial that follow-up studies be carried out to
determine whether T-cell responses as observed here are re-
lated to M. leprae infection or exposure and whether the pres-
ence of this CMI response is indicative of protection against
leprosy or disease development.
FIG. 3. Added value of in vitro T-cell responses to M. leprae anti-
gens. The highest level of IFN- production induced by PBMC against
ML1989, ML1990, ML2283, ML2346, or ML2567 is depicted for EC
individuals (F) and HHCs (Œ) in the context of their seropositivity for
antibodies against PGL-I. The percentages of individuals lacking an-
tibodies against PGL-I (PGL-I) and those responding to 1 of the
M. leprae-unique proteins are indicated above the figure. The total
numbers of individuals that recognize a certain peptide are indicated in
boxes. The threshold for positive responses is indicated by the dotted
line.
TABLE 4. Numbers of individuals with M. leprae-specific anti-PGL-
I IgM antibodies
Group
No. of positive individuals/total no. of individuals (%) for
indicated sitea
A B C D E Total
BL/LL 8/10 8/10 10/10 10/10 10/10 46/50 (92)
BT/TT 0/10 5/10 4/10 4/10 6/10 19/50 (38)
HHC 1/10 3/10 0/10 1/10 2/6 7/46 (15)
EC 0/10 1/10 1/10 1/10 0/10 3/50 (6)
TB 1/10 3/10 1/10 4/10 4/10 13/50 (26)
a Sites: A, Brazil; B, Nepal; C, Bangladesh; D, Karachi; and E, Ethiopia.
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